Skip to main content
. 2017 Jan 11;4(2):76–86. doi: 10.1002/acn3.375

Figure 2.

Figure 2

Targeting microglia and astrocytes leads to additive increase in survival in SOD1‐G93A mice. SOD1‐G93A; IKK β F/wt; CSF1R‐cre− mice and SOD1‐G93A; IKK β F/wt; CSF1R‐cre+ mice received a single intravenous injection of AAV9‐SOD1‐shRNA at postnatal day 21. Injected CSF1R‐cre− (gray) and CSF1R‐cre+ (green) mice and uninjected controls (red and blue) were monitored up to end‐stage of disease. (A) Kaplan–Meier survival analysis of the probability of survival as a function of age in SOD1‐G93A; IKK βF/wt; CSF1R‐cre− (shown in red, n = 33), SOD1‐G93A; IKK βF/wt; CSF‐1R‐cre+ mice (blue, n = 13), CSF1R‐cre− mice injected with SOD1‐shRNA at p21 (gray, n = 14), and CSF1R‐cre+ mice injected with AAV9‐SOD1‐shRNA at p21 (green, n = 13). Median survival: uninjected CSF1R‐cre− = 137 days, uninjected CSF‐1R‐cre+ = 157 days, CSF1R‐cre− p21 injected = 160 days, CSF1R‐cre+ p21 injected = 168 days. (B) Mean survival of mice from uninjected CSF1R‐cre− = 136.9 ± 0.9 days, uninjected CSF‐1R‐cre+ = 157.9 ± 1.8 days, CSF1R‐cre− p21 injected = 158.1 ± 1.8 days, CSF1R‐cre+ p21 injected = 169.8 ± 2.2 days. AAV9, adeno‐associated viral vector serotype 9.***p < 0.001; ****p < 0.0001.